Physician profile
Lee A Hubbert
NPI 1699438572
$4,756.52
in general payments reported to CMS, 2019-2025
22 companies · $2,085 in 2025
The $2,085 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $340 · 2024: $2,332 · 2025: $2,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,756.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,094.24 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $568.35 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $528.98 | 2023-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $511.07 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $242.76 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $210.96 | 2023-2025 | |
| Glaxosmithkline, LLC. | $208.29 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $204.46 | 2023-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $179.91 | 2023-2024 | Yupelri |
| Abbvie INC. | $156.84 | 2024-2025 | |
| Edwards Lifesciences Corporation | $137.50 | 2024 | |
| Astellas Pharma US INC | $135.94 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $96.03 | 2023-2024 | Rexulti |
| Sumitomo Pharma America, INC. | $90.23 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.62 | 2024 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $74.27 | 2024-2025 | Voquezna |
| Verona Pharma, INC. | $67.60 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $64.88 | 2025 | Auvelity |
| Lundbeck LLC | $38.11 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $21.84 | 2025 | Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.75 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $16.89 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Hubbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.